Contraception Methods in Drug Labeling

Drug Information Journal

Volumn 46, Issue 3, 2012, Pages 320-328

  Parotti, Christianne O ^a   Ng, Eric W ^a   Wyszynski, Diego F ^a  

^a AMGEN INC   (United States)

Author keywords

birth control; guidance; label; prescribing information; reproductive toxicity

Indexed keywords

ALPRAZOLAM; ISOTRETINOIN; LEFLUNOMIDE; LISINOPRIL; SATURNIL; THALIDOMIDE; UNCLASSIFIED DRUG; WARFARIN;

CONTRACEPTION; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LABELING; EUROPEAN UNION; FEMALE; HUMAN; PRACTICE GUIDELINE; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TERATOGENICITY; UNITED STATES;

EID: 84864801331     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/0092861512441099     Document Type: Review

References (24)

1. Bonati M,Bortolus R,Marchetti F,Romero M,Tognoni G.Drug use in pregnancy: an overview of epidemiological (drug utilization) studies.Eur J Clin Pharmacol. 1990;38 (4): 325-328.
2. GuQDillonCFBurtVL. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. 2010. http://www.cdc.gov/nchs/data/databriefs/db42.pdf.
3. Daw JR,Hanley GE,Greyson DL,Morgan SG.Prescription drug use during pregnancy in developed countries: a systematic review.Pharmacoepidemiol Drug Saf. 2011;20 (9): 895-902.
4. Mitchell AA,Gilboa SM,Werler MM, et al.Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008.Am J Obstet Gynecol. 2011; (205): e51-58.
5. Schwarz EB,Postlethwaite DA,Hung Y-Y,Armstrong MA.Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.Ann Intern Med. 2007;147 (6): 370-376.
6. Henshaw SK.Unintended pregnancy in the United States.Fam Plann Perspect. 1998;30 (1): 24-29.
7. Centers for Disease Control and Prevention. PRAMS and unintended pregnancy. www.cdc.gov/prams/UP.htm. Accessed March 25, 2011.
8. Food and Drug Administration. Title 21: food and drugs. In: Code of Federal Regulations. Washington DC: US Dept of Health and Human Services; 2011.
9. Schwarz EB,Maselli J,Norton M,Gonzales R.Prescription of teratogenic medications in United States ambulatory practices.Am J Med. 2005;118 (11): 1240-1249.
10. Shrank WH,Avorn J.Educating patients about their medications: The potential and limitations of written drug information.Health Aff. 2007;26 (3): 731-740.
11. CookRJDickensBMWilsonOAFScarrowSE. Advancing safe motherhood through human rights. WHO/RHR/01.5. 2001. http://whqlibdoc.who.int/hq/2001/WHO_RHR_01.5.pdf.
12. WHO. The family planning: A global handbook for providers. 2011. http://whqlibdoc.who.int/publications/2011/9780978856373_eng.pdf. Accessed 12 September 2011.
13. Ng EW,Chiruvolu P,Levy GF,Allan BR,Wyszynski DF.Contraception language in informed consent forms: a survey of biopharmaceutical companies.Drug Information Journal. 2012;46 (3): 329-335.
14. Guideline for the study of gender differences in the clinical evaluation of drugs [FDA guidance for industry]. Fed Regist. 1993;58(139). http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126835.pdf.
15. European Medicines Agency. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126835.pdf. Published July 24, 2008.
16. European Commission - Enterprise and Industry Directorate-General. A guideline on summary of product characteristics (SmPC). http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. Published September2009.
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals
18. Medicines and Healthcare products Regulatory Agency. Clarification of contraceptive wording in clinical trials conducted in the UK. http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2033037.pdf. Published May 21, 2010.
19. CorporationC. System for Thalidomide Education and Prescribing Safety. 2010. http://www.thalomid.com/steps_program.aspx. Accessed October 3, 2011.
20. Stahl O,Boyd HA,Giwercman A, et al.Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries.J Natl Cancer Inst. 2011;103 (5): 398-406.
21. Wyszynski DF.Pregnancy exposure registries: academic opportunities and industry responsibility.Birth Defects Res A Clin Mol Teratol. 2009;85(1):93-101;:.
22. Food and Drug Administration. Reviewer guidance: evaluating the risks of drug exposure in human pregnancies. http://www.fda.gov/downloads/scienceresearch/specialtopics/womenshealthresearch/ucm133359.pdf. Published April2005.
23. Lo WY,Friedman JM.Teratogenicity of recently introduced medications in human pregnancy.Obstet Gynecol. 2002;100 (3): 465-473.
24. Food and Drug Administration. FDA drug safety communication: risk of oral clefts in children born to mothers taking Topamax (topiramate). http://www.fda.gov/Drugs/DrugSafety/ucm245085.htm. Published March 4, 2011.